



It's a Done Deal

\$15,600,000



Follow-On

Sole Placement Agent

FEBRUARY 2023

ROTH MKM Acted as Sole Placement Agent for Tenax Therapeutics, Inc. (Nasdaq: TENX) in its \$15.6 Million Follow-On

For more information please contact:

Investment Banking

James Antonopoulos
Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906
jantonopoulos@roth.com

Aparna Beeram
Vice President
(646) 358-1912
abeeram@roth.com

Equity Capital Markets

Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
agurewitz@roth.com

Nazan Akdeniz
Managing Director

Transaction Information

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced the pricing of a public offering of (i) 8,666,666 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 17,333,332 shares of its common stock (the "Public Warrants") at a purchase price of \$1.80 per share and associated Public Warrant. The Public Warrants will have an exercise price of \$2.25 per share, are immediately exercisable, and will expire five years after their initial exercise date. The offering closed on February 7, 2023.

Roth Capital Partners acted as sole placement agent for the offering.

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. Tenax Therapeutics is developing a unique oral

(949) 720-5740
nakdeniz@roth.com

Lou Ellis
Managing Director
(949) 720-5739
lellis@roth.com

formulation of imatinib. The Company also owns North American rights to develop and commercialize subcutaneous and oral formulations of levosimendan. For further information about the Company, please visit www.Tenaxthera.com (Source: Company Website 2.3.23)

About ROTH MKM

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading](#)
[Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

Date of Announcement: 2.10.23

The material, information and facts discussed in this announcement other than the information regarding Roth Capital Partners, LLC ("Roth") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2023.

Roth Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | www.roth.com

